Beransa (Arthritis Injections) - Should we be concerned?

In recent months, Beransa—an innovative treatment for canine osteoarthritis—has found itself in the spotlight for reasons that have understandably raised questions among pet owners. Media reports and personal stories have highlighted adverse reactions in some dogs, prompting concern and even calls for regulatory review.

At our clinic, we believe it’s important to acknowledge these concerns openly and honestly. We also believe in the power of balanced information, clinical experience, and above all, individualised care.

🧬 What Is Beransa?

Beransa (bedinvetmab) is a monoclonal antibody therapy designed to target nerve growth factor (NGF), a key player in transmitting pain signals in osteoarthritic joints. It’s not a painkiller in the traditional sense—it’s a targeted biological treatment, administered via monthly injection, and has been a game-changer for many dogs who didn’t respond well to conventional therapies.

📰 Addressing the Concerns

Recent press has highlighted cases where dogs experienced serious side effects, including neurological symptoms and immune-mediated conditions. These stories are deeply upsetting, and we extend our compassion to the families affected.

It’s also important to understand that:

All medications carry risks, and Beransa is no exception.

The Australian Pesticides and Veterinary Medicines Authority (APVMA) continues to monitor Beransa closely and has updated its label to reflect rare but serious side effects.

The manufacturer, Zoetis, has restricted Beransa’s supply to veterinary clinics only, ensuring it is administered under the professional supervision of a veterinary surgeon.

🩺 Our Approach: Thoughtful, Tailored, Transparent

We continue to use Beransa in our clinic—not because we ignore the risks, but because we’ve seen genuine improvements in many of our patients’ quality of life. Dogs who were once reluctant to move are now walking, playing, and engaging again.

Every medication prescribed is thoroughly considered by our vets.  

We assess each patient individually, considering age, health status, concurrent medications, and lifestyle.

We discuss risks and benefits openly with pet owners.

We monitor closely, especially during the first few months of treatment.  Monitoring may look like blood tests, repeat examinations with the vet, and verbal discussions on how you, the owner, feels your pet is responding to treatment.  

And if Beransa isn’t the right fit, we explore other options—because there is no one-size-fits-all solution in the management of osteoarthritis, and really all aspects of veterinary medicine!

🐶 Informed Decisions, Compassionate Care

We understand that headlines can be alarming. But behind every treatment decision is a conversation, a clinical judgment, and a commitment to doing what’s best for your dog. If you have questions or concerns about Beransa—or any medication—please reach out. We’re here to listen, explain, and guide you through the choices with empathy and expertise.

‍

‍